The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2015

Filed:

Jan. 20, 2011
Applicants:

J. Brice Weinberg, Durham, NC (US);

Warren J. Strittmatter, Hillsborough, NC (US);

Inventors:

J. Brice Weinberg, Durham, NC (US);

Warren J. Strittmatter, Hillsborough, NC (US);

Assignee:

Duke University, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 31/437 (2006.01); A61K 31/4433 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7056 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/4433 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7056 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); G01N 33/57426 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided.


Find Patent Forward Citations

Loading…